Company Profile

Indevr Inc
Profile last edited on: 2/24/23      CAGE: 3G9T5      UEI: CX4ZCPH2EAA3

Business Identifier: Novel analytical technologies for biologic process development and monitoring,
Year Founded
2003
First Award
2004
Latest Award
2017
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2100 Central Avenue Suite 106
Boulder, CO 80301
   (303) 402-9100
   indevr@indevr.com
   www.indevr.net
Location: Single
Congr. District: 02
County: Boulder

Public Profile

InDevR is a biotech company developing advanced life science instrumentation and assays for analysis of viruses and other microorganisms, as well as protein detection and characterization, with product focus on Virus Quantification and pathogen detection/identification. Founded in 2003, shortly thereafter management purchased majority ownership of 2B Technologies, a leader in the field of analytical instruments for atmospheric and environmental measurements. An ISO 9001:2000-certified manufacturer, 2B Technologies has produced and sold over 2,000 ozone monitors and related instruments. In 2012, InDevR spun off the Virus Counter Instrument to ViroCyt, LCC. The focus of InDevR's efforts has since become that of the development and commercialization of their low-density microarray technology, which can be used to improve the analysis of viruses and other microorganisms as well as detecting and characterizing proteins.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 NIH $3,921,832
Project Title: Titer on Chip: Alternative to Srid for Influenza Vaccine Potency Determination
2017 2 NIH $2,591,388
Project Title: Innovative Optical System for Hemagglutination Assays
2013 2 NIH $3,546,051
Project Title: Simultaneous Screening for A/H3N2, A/H1N1, A/H5N1 and B Influenza Viruses
2010 2 NIH $3,123,581
Project Title: Monitoring System for Vector-Based Influenza Vaccine
2005 2 NIH $932,297
Project Title: Advanced Detection Technologies for Biochips

Key People / Management

  Kathy L Rowlen -- Chief Executive Officer and Co-founder

  John Birks -- Executive Vice President and Co-founder

  Dawn Bitz -- Chief Commercial Officer

  Erica D Dawson -- Chief Technical Officer

  Laura Kuck -- Executive Vice President and Co-founder

  Michael Minard -- Director of Business Development

  Shannon Rodriguez -- Director of Finance

  Shannon Rodriguez -- Chief Operations Officer

  Terry Salyer -- Chief Commercial Officer

  Cyndi Woodward